Last reviewed · How we verify
Neostigmine + Atropine
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while atropine blocks muscarinic receptors to counteract excessive parasympathomimetic effects.
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while atropine blocks muscarinic receptors to counteract excessive parasympathomimetic effects. Used for Myasthenia gravis, Postoperative ileus and urinary retention, Reversal of neuromuscular blockade.
At a glance
| Generic name | Neostigmine + Atropine |
|---|---|
| Also known as | N.group |
| Sponsor | China Medical University Hospital |
| Drug class | Cholinesterase inhibitor + Anticholinergic agent |
| Target | Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (atropine) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Neostigmine is a cholinesterase inhibitor that prevents the breakdown of acetylcholine, thereby enhancing cholinergic neurotransmission. Atropine is an anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing parasympathomimetic side effects such as excessive salivation, bronchospasm, and bradycardia. This combination allows neostigmine's therapeutic benefits (improved muscle strength and neuromuscular transmission) while mitigating its adverse effects.
Approved indications
- Myasthenia gravis
- Postoperative ileus and urinary retention
- Reversal of neuromuscular blockade
Common side effects
- Dry mouth
- Blurred vision
- Tachycardia
- Urinary retention
- Constipation
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- A Comparative Study Between Combination of Propofol and Dexmedetomidine Versus Propofol Alone in Anesthesia for Rigid Bronchoscopy by Using the Patient State Index Monitor (PHASE4)
- NMBA Reversal and Postoperative Urinary Retention
- Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery (PHASE3)
- Emergence Agitation (NA)
- Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169) (PHASE4)
- Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery (NA)
- Using Diaphragm Ultrasonography, Sugammadex Recovers Diaphragmatic Function More Effectively Than Neostigmine. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neostigmine + Atropine CI brief — competitive landscape report
- Neostigmine + Atropine updates RSS · CI watch RSS
- China Medical University Hospital portfolio CI